MTM Pediatric Obesity Practice Test

These questions are part of the practice quiz. Start practicing

• Which is an endocrine consequence of pediatric obesity?
• When screening adolescents with obesity, under what circumstances should liver enzymes be considered?
• Intestinal CYP3A4 activity in obesity tends to what?
• SMART goals in pediatric obesity are defined as:
• Which of the following is a common side effect of Orlistat?
• Which of the following are examples of MTM outputs?
• Which statement best describes disease management?
• Which BMI percentile ranges define weight status categories in children?
• What is a known caution with phentermine due to its mechanism?
• What is a required characteristic of MTM programs for Medicare Part D Plans and MAPDs?
• Which medication category showed an increase in controller medication use?
• If a clinician suspects Cushing syndrome in a child with obesity, what is the recommended action?
• What is a key principle of MTM related to patient involvement?
• Which agent is not approved for weight management because of its relatively low efficacy?
• In pediatric obesity, how is gastric emptying typically affected?
• What is the effect on solubilization and absorption in the stomach with obesity?
• Which of the following is NOT listed as a medication associated with weight gain in pediatric populations?
• The phentermine/topiramate combination is contraindicated in which condition?
• Which item is a component of the proposed MTM model?
• How is 'intensive behavioral therapy' defined in pediatric obesity?
• Which percentile is used as reference for obesity classifications?
• What sleep and screen-time guidance is recommended for pediatric obesity care?
• Which clinical sign suggests obesity-related comorbidities in youth?
• What was the estimated prevalence of chronic disease or conditions in children?
• Of the following medications, which one is not approved for weight management because of limited efficacy?
• When pharmacotherapy is prescribed, clinicians should provide or refer to what?
• How is severe pediatric obesity defined in relation to the 95th percentile?
• Which finding raises concern for fatty liver disease in a child with obesity?
• Which statement best describes MTM's ongoing management focus?
• What is waist circumference measurement useful for in obesity risk assessment?
• At what age should routine obesity screening begin in most pediatric guidelines?
• What non-clinical factor most strongly influences adherence to obesity treatment in youth?
• What threshold defines severe obesity in BMI percentiles?
• Which of the following is a common barrier to adherence in pediatric obesity treatment?
• Targeted medication therapy review is described as which of the following?
• Which liver-related gastrointestinal consequence is associated with pediatric obesity?
• Which statement best describes the liver effect on drug bioavailability?
• What is mid-dose phentermine-topiramate?
• What rate of home chemotherapy administration errors occurred per 100 patients in one pediatric study?
• NAFLD stands for which term?
• What is achieved with MTM?
• What is the role of a dietitian in pediatric obesity care?
• TBW-based dosing is not universally correct; it overcorrects for which type of drugs?
• Which symptom may indicate sleep-disordered breathing associated with pediatric obesity?
• Which organization endorses comprehensive, intensive behavioral therapy for children with obesity, implemented via primary care and specialists?
• Among therapies for weight management, which medication is not approved for weight management because of low efficacy?
• Which trend indicates health care reform increasing pressure for measurable quality coordination and value-based outcomes?
• How should eating-disorder risk be addressed in weight management?
• Intestinal bioavailability with obesity is affected how?
• Regarding GLP-1 medications, which statement is true about obesity?
• How does culturally tailored care influence outcomes in pediatric obesity?
• What is a common caution with Metformin use for pediatric obesity?
• Which obesity medication is approved for pediatric obesity in patients over 12 years but often poorly tolerated?
• Which organization is associated with endorsing comprehensive behavioral therapy guidelines for pediatric obesity?
• Which statement about the study findings is true regarding undertreated issues?
• Which medication has a specific role for a rare genetic obesity option in adolescents aged 6 and older?
• Which respiratory condition is linked to pediatric obesity?
• Guidelines emphasize that pharmacotherapy for pediatric obesity should be used in conjunction with what?
• Which statement best represents an MTM outcome related to therapy goals?
• Which low efficacy medication is NOT approved for weight management?
• Overweight in pediatric BMI percentiles is defined as which range?
• What is the focus of MTM?
• How is hepatic blood flow described in obesity-related liver changes?
• What is a core principle of effective family-based lifestyle intervention?
• The study suggested that these optimization issues were routine problems that a structured pharmacist review could surface.
• Healthy weight in pediatric BMI percentiles is defined as which range?
• How does puberty affect obesity assessment and management?
• NASH stands for which condition?
• Pharmacotherapy should be considered in which patient group?
• Which option is NOT listed as a high-risk pediatric medication group?
• What is the starting dose of semaglutide when used for obesity?
• Which problems affected roughly one-third of the study cohort according to the findings?
• Which liver condition is associated with obesity and described in the material?
• Which drug is NOT approved for weight management because it has low efficacy?
• What is the starting dose of setmelanotide?
• Class III obesity is defined as which range relative to the 95th percentile?
• When is a global review of all medications recommended for pediatric patients?
• Which of the following drugs is not approved for weight management because of its low efficacy?
• Among common anti-obesity medications, which is NOT approved for weight management due to limited efficacy?
• Topiramate may cause which type of adverse effects?
• What is the high-dose phentermine-topiramate combination?
• Which of the following is considered an endocrine consequence?
• Which statement about targeted MTR is true?
• How should obesity management be adapted for youth with orthopedic limitations or mobility issues?
• Which of the following are core techniques of motivational interviewing in pediatric obesity management?
• How does socioeconomic status affect pediatric obesity prevalence and care?
• Why is energy balance central to obesity treatment?
• Which statement is NOT a design principle for MTM documentation?
• Between 2002 and 2005, what was the reported increase in antidiabetic medication use?
• Name three common comorbidity screenings recommended at initial obesity evaluation.
• From the following, which medication is not approved for weight management due to low efficacy?
• Which medication is a short-term appetite suppressant option for individuals aged 16 and older?
• Which tests may be used to evaluate suspected Cushing syndrome in a child with obesity?
• Which dermatologic finding is associated with pediatric obesity?
• Which term best describes liver effect on bioavailability (HPFE)?
• Which of the following is NOT a strategy to reduce consumption of sugar-sweetened beverages?
• Choose the medication that is not approved for weight management because of low efficacy.
• Which GLP-1 receptor agonist is listed as a prominent option for obesity management in youths aged 12 years and older?
• Which medication is known to be associated with weight gain in pediatric patients?
• Which metric beyond weight should be monitored during follow-up?
• What is the starting oral dose of phentermine/topiramate?
• A fixed (non-weight-based) dose tends to do which in obese patients?
• Which endocrine consequence includes effects on growth and puberty?
• Gallbladder volume changes described in the material?
• What is the recommended first-line approach for very young children with overweight or obesity?
• What is a caution with the phentermine/topiramate combination regarding monitoring?
• How is progress typically monitored during a pediatric obesity behavioral program?
• What is prevented with MTM?
• Medication-related harm accounted for what range of hospitalizations?
• JPPT White Paper recommendations suggest dosing in children with overweight or obesity should be what?
• Which of the following is listed as a high-risk medication group in pediatrics?
• Which statement best describes the role of lipophilicity in obesity-related drug distribution?
• Which adverse effects are commonly associated with orlistat and should be discussed with families?
• Which option best describes prescription dispensing?
• Which combination is used with lifestyle modification in ages 12+?
• Which of the following represents the correct physical activity target for youth with obesity?
• What are school-based physical activity guidelines for children?
• Which statement correctly describes MTM's relationship to prescription dispensing and disease management?
• What strategies can help reduce consumption of sugar-sweetened beverages?
• Identify the medication that is not approved for weight management because of low efficacy.
• Which statement about NAFLD and NASH is accurate?
• Which drug is listed as associated with weight gain in pediatric patients?
• What is the relationship between sleep duration and obesity risk in children?
• In PMR design, which phrasing is preferred over “indication”?
• What is a key system design principle for MTM documentation?
• What is the maximum daily dose of setmelanotide?
• Which listed medication fails to have approval for weight management due to low efficacy?
• What is a cornerstone of first-line dietary management for pediatric obesity?
• Which trend notes the use of chronic meds across multiple classes?
• Metformin's efficacy data for obesity treatment in youth is described as what?
• When might pharmacotherapy or bariatric options be considered in pediatric obesity?
• Which statement about CYP3A4 activity is true in obesity-related liver changes?
• In obesity, what happens to intestinal motility?
• Where is comprehensive, intensive behavioral therapy typically implemented?
• In pediatric BMI percentiles, underweight is defined as what?
• Which medication is NOT approved as a weight management option due to low efficacy?
• Reported CAM use among children in the US per 2012 survey?
• What is the significance of school-based interventions in obesity prevention and treatment?
• Which factor is associated with about a 3.3-fold increase in medication error risk in pediatrics?
• What is a primary purpose of intensive behavioral therapy components in pediatric obesity?
• Which step is the final step in the proposed MTM model?
• Which trend notes risk due to complementary and alternative medicine?
• How should management differ for toddlers versus adolescents with obesity?
• Which medication is commonly used off-label for obesity in children?
• In pharmacologic options for weight management, which drug is not approved due to low efficacy?
• Which is a PMR design principle?
• What percentage increase was observed in ADHD medication use in the chronic medication trend analysis?
• Which statement best aligns with the dietary approach to pediatric obesity management?
• What is the focus of disease management?
• According to guidelines, what is the evidence for using weight loss medications as monotherapy in pediatric obesity?
• In the Children's Hospital Colorado study, unnecessary therapy and suboptimal therapy were each found in about what percentage of patients?
• What growth-related measurements should be tracked to ensure healthy growth during obesity management?
• Besides BMI percentile, which measurement helps assess central adiposity and metabolic risk in youth?
• Which liver finding is listed as part of obesity-related hepatic changes?
• What is a key communication principle when discussing obesity with families?
• What is recommended for children aged 2-5 with overweight or obesity regarding dieting?
• Which weight-management medication is not approved owing to low efficacy?
• Which endocrine disorder should be considered in the differential diagnosis of pediatric obesity?
• Which psychosocial consequence is commonly observed in pediatric obesity?
• In one ambulatory pediatric study, what percent of prescriptions were over- or under-diagnosed?
• What is the typical duration and structure of a comprehensive behavioral therapy program for obesity?
• Which cardiometabolic risk factors should be screened in adolescents with obesity?
• What best describes a Personal Medication Record (PMR)?
• Which trend is cited as driving MTM in pediatrics due to disease burden?
• HFPE stands for which pharmacokinetic concept?
• Which outcome beyond physical measures should be considered when evaluating obesity treatment in youth?
• Why should restrictive dieting be avoided in weight management for youth?
• When is NAFLD screening considered in obese youth?
• Which statement reflects a MAP design principle?
• Which dietary education topic should be covered when initiating weight management?
• Which is a cardiovascular consequence of pediatric obesity?
• Class I obesity is defined as which range relative to the 95th percentile?
• What is the standard clinical measure used to screen for overweight and obesity in children and adolescents?
• Which statement best reflects central adiposity assessment in youth obesity?
• What are the primary physical activity targets for most children and adolescents with obesity?
• In guidelines for weight management pharmacotherapy, which medication is not approved due to low efficacy?